Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Carcinoma, Non-Small-Cell Lung 17Lymphoma, Large-Cell, Anaplastic 6Lung Neoplasms 6Neoplasm Metastasis 5Adenocarcinoma 4Neuroblastoma 2Neoplasms 2Carcinoma, Squamous Cell 2Carcinoma 2Uveal Melanoma 1Triple Negative Breast Neoplasms 1Stomach Neoplasms 1Solid Tumors 1Sarcoma, Clear Cell 1Sarcoma, Alveolar Soft Part 1Rhabdomyosarcoma, Alveolar 1Recurrence 1Neurofibromatosis 2 1Lymphoma, Follicular 1Granuloma, Plasma Cell 1Glioma 1Glioblastoma 1Diffuse Intrinsic Pontine Glioma 1Colorectal Neoplasms 1Castration-resistant Prostate Cancer 1Carcinoma, Renal Cell 1Carcinoma, Lobular 1Carcinoma, Large Cell 1Advanced Cancer 1ALK-positive NSCLC 1

Interventions

enzalutamide 4Abiraterone Acetate 2radium Ra 223 dichloride 1dactolisib 1abiraterone 1VT-464 1Prednisone 1NVP-BKM120 1Flutamide 1Crizotinib 1Control Groups 1Blood Specimen Collection 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Castration-resistant Prostate Cancer × Crizotinib × Clear all
NCT02207504 2022-01-06

Crizotinib in Combination With Enzalutamide in Metastatic Castration-resistant Prostate Cancer

Dana-Farber Cancer Institute

Phase 1 Completed
24 enrolled
Genitourinary

Castration-resistant Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡